Stančík Matej, Grendár Marián, Mokáň Marián
Department of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Bratislava, Slovak Republic.
Laboratory of Bioinformatics and Biostatistics, Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Bratislava, Slovak Republic.
Sci Rep. 2025 Feb 4;15(1):4254. doi: 10.1038/s41598-025-88332-6.
Carboxypeptidase B1 has long been known to be a pancreas-specific tissue enzyme. In this paper we focus on Carboxypeptidase B1 concentration measurement in dialyzed chronic kidney kidney disease patients and on the effect dialysis adequacy and regimen exert on its concentration. A total of 142 subjects were divided into control and target groups. In the target group two measurements of plasma Carboxypeptidase B1 one month apart were conducted with the use of Carboxypeptidase B1 ELISA kit. The mean Carboxypeptidase B1 concentration was significantly higher in the target arm compared to the control arm (77.60 ± 11.81 ng/mL and 1.22 ± 0.41 ng/mL, respectively; p < 0.001). Generalized linear mixed regression revealed that affiliation with the control arm was the only significant contributor of this finding. Linear mixed model regression revealed that dialysis regimen that represents number of dialyses per one week-long cycle is a significant predictor of Carboxypeptidase B1 concentration. Exploration of the estimated marginal means of Carboxypeptidase B1 revealed that the Carboxypeptidase B1 concentration was significantly higher among patients on twice per week dialysis regimen than among those treated with three dialysis sessions per week.
长期以来，人们一直认为羧肽酶B1是一种胰腺特异性组织酶。在本文中，我们重点关注透析慢性肾病患者中羧肽酶B1浓度的测量，以及透析充分性和方案对其浓度的影响。总共142名受试者被分为对照组和目标组。在目标组中，使用羧肽酶B1 ELISA试剂盒，相隔一个月进行两次血浆羧肽酶B1测量。目标组的平均羧肽酶B1浓度显著高于对照组（分别为77.60±11.81 ng/mL和1.22±0.41 ng/mL；p<0.001）。广义线性混合回归显示，与对照组的关联是这一发现的唯一显著因素。线性混合模型回归显示，代表每一个为期一周的周期内透析次数的透析方案是羧肽酶B1浓度的显著预测因子。对羧肽酶B1估计边际均值的探索显示，每周透析两次方案的患者中羧肽酶B1浓度显著高于每周透析三次的患者。
